//
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors
Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial